Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Burosumab (KRN23) in Pediatric X-linked Hypophosphatemia
2016-000600-29Phase 3Terminated
- Sponsor
- Ultragenyx Therapeutics
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of burosumab in X-linked hypophosphataemia (XLH) and Hereditary Hypophosphatemic Rickets (XLH) (2 arms), sponsored by Ultragenyx Therapeutics. Started Jun 2016; status: terminated.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)Hereditary Hypophosphatemic Rickets (XLH)
Beyond the preview
Go deeper on 2016-000600-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000600-29.